High Efficacy Combined Microneedles Array with Methotrexate Nanocrystals for Effective Anti-Rheumatoid Arthritis

References

• Symmons DP. Looking back: rheumatoid arthritis–aetiology, occurrence and mortality. Rheumatology. 2005;Suppl 44(suppl_4):iv14–iv17. doi:10.1093/rheumatology/kei055
   Web of Science ®Google Scholar
• Van der Woude D, Van der Helm-van MA. Update on the epidemiology, risk factors, and disease outcomes of rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2018;32(2):174–187. doi:10.1016/j.berh.2018.10.005
   PubMed Web of Science ®Google Scholar
• Colmegna I, Ohata BR, Menard HA. Current understanding of rheumatoid arthritis therapy. Clin Pharmacol Ther. 2012;91(4):607–620. doi:10.1038/clpt.2011.325
   PubMed Web of Science ®Google Scholar
• Choi SI, Brahn E. Rheumatoid arthritis therapy: advances from bench to bedside. Autoimmunity. 2010;43(7):478–492. doi:10.3109/08916931003674717
   PubMed Web of Science ®Google Scholar
• Kim-Howard XR, Staudt L, James JA. Update in rheumatoid arthritis therapy. J Okla State Med Assoc. 2005;98(2):53–62.
   PubMedGoogle Scholar
• Abbasi M, Mousavi M J, Jamalzehi S, et al. Strategies toward rheumatoid arthritis therapy; the old and the new. J Cell Physiol. 2019;234(7):10018–10031. doi:10.1002/jcp.27860
   PubMed Web of Science ®Google Scholar
• Fraenkel L, Bathon J M, England BR, et al. 2021 American college of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 2021;73(7):924–939. doi:10.1002/acr.24596
   PubMed Web of Science ®Google Scholar
• Fu Q, Feng P, Sun LY, et al. A double-blind, double-dummy, randomized controlled, multicenter trial of 99Tc-methylene diphosphonate in patients with moderate to severe rheumatoid arthritis. Chin Med J. 2021;134(12):1457–1464. doi:10.1097/CM9.0000000000001527
   PubMed Web of Science ®Google Scholar
• Olofsson T, Wallman JK, Joud A, et al. Pain over two years after start of biologic versus conventional combination treatment in early rheumatoid arthritis: results from a Swedish randomized controlled trial. Arthritis Care Res. 2021;73(9):1312–1321. doi:10.1002/acr.24264
   Web of Science ®Google Scholar
• Emery P, Tanaka Y, Cardillo T, et al. Temporary interruption of baricitinib: characterization of interruptions and effect on clinical outcomes in patients with rheumatoid arthritis. Arthritis Res Ther. 2020;22(1):115. doi:10.1186/s13075-020-02199-8
   PubMed Web of Science ®Google Scholar
• Bianchi G, Caporali R, Todoerti M, et al. Methotrexate and rheumatoid arthritis: current evidence regarding subcutaneous versus oral routes of administration. Adv Ther. 2016;33(3):369–378. doi:10.1007/s12325-016-0295-8
   PubMed Web of Science ®Google Scholar
• Vena GA, Cassano N, Iannone F. Update on subcutaneous methotrexate for inflammatory arthritis and psoriasis. Ther Clin Risk Manag. 2018;14:105–116. doi:10.2147/TCRM.S154745
   PubMed Web of Science ®Google Scholar
• Jay R. Methotrexate revisited: considerations for subcutaneous administration in RA. Clin Rheumatol. 2015;34(2):201–205. doi:10.1007/s10067-014-2830-9
   PubMed Web of Science ®Google Scholar
• Hugle B. MTX intolerance in children and adolescents with juvenile idiopathic arthritis. Z Rheumatol. 2019;78(7):620–626. doi:10.1007/s00393-019-0644-5
   PubMed Web of Science ®Google Scholar
• Artacho A, Isaac S, Nayak R, et al. The pretreatment gut microbiome is associated with lack of response to methotrexate in new-onset rheumatoid arthritis. Arthritis Rheumatol. 2021;73(6):931–942. doi:10.1002/art.41622
   PubMed Web of Science ®Google Scholar
• Jekic B, Lukovic L, Bunjevacki V, et al. Association of the TYMS 3G/3G genotype with poor response and GGH 354GG genotype with the bone marrow toxicity of the methotrexate in RA patients. Eur J Clin Pharmacol. 2013;69(3):377–383. doi:10.1007/s00228-012-1341-3
   PubMed Web of Science ®Google Scholar
• Tu X, Chen R, Huang G, et al. Factors predicting severe myelosuppression and its influence on fertility in patients with low-risk gestational trophoblastic neoplasia receiving single-agent methotrexate chemotherapy. Cancer Manag Res. 2020;12:4107–4116. doi:10.2147/CMAR.S252664
   PubMed Web of Science ®Google Scholar
• Nakafero G, Grainge MJ, Card T, et al. What is the incidence of methotrexate or leflunomide discontinuation related to cytopenia, liver enzyme elevation or kidney function decline? Rheumatology. 2021;60(12):5785–5794. doi:10.1093/rheumatology/keab254
   PubMed Web of Science ®Google Scholar
• Pivovarov K, Zipursky JS. Low-dose methotrexate toxicity. CMAJ. 2019;191(15):E423. doi:10.1503/cmaj.181054
   PubMed Web of Science ®Google Scholar
• Alfaro-Lara R, Espinosa-Ortega HF, Arce-Salinas CA. Systematic review and meta-analysis of the efficacy and safety of leflunomide and methotrexate in the treatment of rheumatoid arthritis. Reumatol Clín. 2019;15(3):133–139. doi:10.1016/j.reuma.2017.07.020
   PubMed Web of Science ®Google Scholar
• Blair HA, Deeks ED. Abatacept: a review in rheumatoid arthritis. Drugs. 2017;77(11):1221–1233. doi:10.1007/s40265-017-0775-4
   PubMed Web of Science ®Google Scholar
• Kerschbaumer A, Sepriano A, Smolen JS, et al. Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis. 2020;79:744–759. doi:10.1136/annrheumdis-2019-216656
   PubMed Web of Science ®Google Scholar
• Salliot C, van der Heijde D. Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann Rheum Dis. 2009;68(7):1100–1104. doi:10.1136/ard.2008.093690
   PubMed Web of Science ®Google Scholar
• W LJ, Choi SO, Felner EI, et al. Dissolving microneedle patch for transdermal delivery of human growth hormone. Small. 2011;7(4):531–539. doi:10.1002/smll.201001091
   PubMed Web of Science ®Google Scholar
• Li Y, Hu X, Dong Z, et al. Dissolving microneedle arrays with optimized needle geometry for transcutaneous immunization. Eur J Pharm Sci. 2020;151:105361. doi:10.1016/j.ejps.2020.105361
   PubMed Web of Science ®Google Scholar
• Hao Y, Li W, Zhou X, et al. Microneedles-based transdermal drug delivery systems: a review. J Biomed Nanotechnol. 2017;13(12):1581–1597. doi:10.1166/jbn.2017.2474
   PubMed Web of Science ®Google Scholar
• Yang H, Wu X, Zhou Z, et al. Enhanced transdermal lymphatic delivery of doxorubicin via hyaluronic acid based transfersomes/microneedle complex for tumor metastasis therapy. Int J Biol Macromol. 2019;125:9–16. doi:10.1016/j.ijbiomac.2018.11.230
   PubMed Web of Science ®Google Scholar
• Lopez-Ramirez MA, Soto F, Wang C, et al. Built-in active microneedle patch with enhanced autonomous drug delivery. Adv Mater. 2020;32(1):e1905740. doi:10.1002/adma.201905740
   PubMed Web of Science ®Google Scholar
• Karadag A, Ozcelik B, Huang Q. Quercetin nanosuspensions produced by high-pressure homogenization. J Agric Food Chem. 2014;62(8):1852–1859. doi:10.1021/jf404065p
   PubMed Web of Science ®Google Scholar
• Pardhi VP, Verma T, Flora S, et al. Nanocrystals: an overview of fabrication, characterization and therapeutic applications in drug delivery. Curr Pharm Des. 2018;24(43):5129–5146. doi:10.2174/1381612825666190215121148
   PubMed Web of Science ®Google Scholar
• Shah R, Soni T, Shah U, et al. Formulation development and characterization of lumefantrine nanosuspension for enhanced antimalarial activity. J Biomater Sci Polym Ed. 2021;32(7):833–857. doi:10.1080/09205063.2020.1870378
   PubMed Web of Science ®Google Scholar
• Goel S, Sachdeva M, Agarwal V. Nanosuspension technology: recent patents on drug delivery and their characterizations. Recent Pat Drug Deliv Formul. 2019;13(2):91–104. doi:10.2174/1872211313666190614151615
   PubMedGoogle Scholar
• Chan KH, Lee WH, Ni M, et al. C-Terminal residue of ultrashort peptides impacts on molecular self-assembly, hydrogelation, and interaction with small-molecule drugs. Sci Rep. 2018;8(1). doi:10.1038/s41598-018-35431-2.
   Web of Science ®Google Scholar
• Gigliobianco MR, Casadidio C, Censi R, et al. Nanocrystals of poorly soluble drugs: drug bioavailability and physicochemical stability. Pharmaceutics. 2018;10(3):134. doi:10.3390/pharmaceutics10030134
   PubMed Web of Science ®Google Scholar
• Dos SA, Carvalho FC, Teixeira DA, et al. Computational and experimental approaches for development of methotrexate nanosuspensions by bottom-up nanoprecipitation. Int J Pharm. 2017;524(1–2):330–338. doi:10.1016/j.ijpharm.2017.03.068
   PubMed Web of Science ®Google Scholar